A Phase 3 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir and ribavirin in Hepatitis C Virus (HCV), sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-10.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ombitasvir in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. ombitasvir · Hepatitis C.
Among the 26 studies testing ombitasvir in Hepatitis C, this one is the 17th largest by enrollment, is one of 9 that started in 2015, is one of 15 in phase 3, and was the 25th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 26 studies testing ombitasvir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
ombitasvir: first FDA approval 2014 (VIEKIRA PAK (COPACKAGED)), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 143 across the 26 interventional studies. Of the 25 that completed or were terminated, 23 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 26 have an industry lead sponsor. The 6 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
90 studies in Hepatitis C by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 88 finished, 71 (81%) have results posted.
Among the 90 studies in Hepatitis C by AbbVie, this one is the 43rd largest by enrollment of the 74 interventional ones that give a count, is one of 19 that started in 2015, is one of 46 in phase 3, and was the 56th registered.
AbbVie’s Hepatitis C studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing ombitasvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 90 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study seeks to assess the safety and efficacy of treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in non-cirrhotic, genotype 1a (GT1a) hepatitis C virus infected participants who are treatment-naïve or treatment-experienced with Interferon (IFN) or Pegylated Interferon (pegIFN) with or without Ribavirin (RBV).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) plus RBV (ribavirin \[600 mg once daily\]) for 12 weeks.
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin
Drug pages: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir
Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Also known as: Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333
Tablet
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. The primary efficacy endpoint was noninferiority of the percentage of participants who achieved SVR12 in participants in the treatment arm 3-DAA + RBV 600 mg) for 12 weeks compared with the historical control rate for subjects treated with 3-DAA + weight-based RBV for 12 weeks.
Time frame: 12 weeks after the last actual dose of study drug
Percentage of Participants With Hemoglobin < 10 g/dL During Treatment
The percentage of participants with hemoglobin \<10 g/dL during treatment is provided.
Time frame: up to 12 weeks
Mean Change in Hemoglobin Values From Baseline to End of Treatment
The mean change in hemoglobin (g/L) from baseline to each study visit and to the final treatment visit (up to 12 weeks) is provided.
Time frame: Baseline (Day 1) to Weeks 2, 4, 8, and 12, and the Final Treatment Visit (up to 12 weeks)
Percentage of Participants With On-treatment Virologic Failure
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment.
Time frame: Up to 12 weeks
Percentage of Participants With Post-treatment Relapse
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug, excluding reinfection, among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.
Time frame: From the end of treatment through 12 weeks after the last dose of study drug
| Milestone | 3-DAA + RBV 600 mg |
|---|---|
| Started | 105 |
| Completed | 97 |
| Not completed | 8 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Other | 1 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. The primary efficacy endpoint was noninferiority of the percentage of participants who achieved SVR12 in participants in the treatment arm 3-DAA + RBV 600 mg) for 12 weeks compared with the historical control rate for subjects treated with 3-DAA + weight-based RBV for 12 weeks.
| percentage of participants | 3-DAA + RBV 600 mg |
|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) | 89.5 (83.7 to 95.4) |
The percentage of participants with hemoglobin \<10 g/dL during treatment is provided.
| percentage of participants | 3-DAA + RBV 600 mg |
|---|---|
| Percentage of Participants With Hemoglobin < 10 g/dL During Treatment | 0 |
The mean change in hemoglobin (g/L) from baseline to each study visit and to the final treatment visit (up to 12 weeks) is provided.
| g/L | 3-DAA + RBV 600 mg |
|---|---|
| Week 2 | -6.4 ± 8.17 |
| Week 4 | -8.9 ± 9.37 |
| Week 8 | -11.2 ± 9.85 |
| Week 12 | -12.4 ± 10.06 |
| Final Treatment Visit | -12.1 ± 9.90 |
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment.
| percentage of participants | 3-DAA + RBV 600 mg |
|---|---|
| Percentage of Participants With On-treatment Virologic Failure | 1.0 |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug, excluding reinfection, among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.
| percentage of participants | 3-DAA + RBV 600 mg |
|---|---|
| Percentage of Participants With Post-treatment Relapse | 4.1 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3-DAA + RBV 600 mg | — | 3/105 (2.9%) | 53/105 (50.5%) |
| Event | 3-DAA + RBV 600 mg |
|---|---|
| CYCLIC VOMITING SYNDROMEGastrointestinal disorders | 1/105 |
| BIPOLAR I DISORDERPsychiatric disorders | 1/105 |
| PSYCHOTIC DISORDERPsychiatric disorders | 1/105 |
| Event | 3-DAA + RBV 600 mg |
|---|---|
| FATIGUEGeneral disorders | 29/105 |
| HEADACHENervous system disorders | 14/105 |
| INSOMNIAPsychiatric disorders | 12/105 |
| NAUSEAGastrointestinal disorders | 11/105 |
| DIARRHOEAGastrointestinal disorders | 9/105 |
| ANXIETYPsychiatric disorders | 7/105 |
| CONSTIPATIONGastrointestinal disorders | 6/105 |
| INFLUENZAInfections and infestations | 6/105 |
| BACK PAINMusculoskeletal and connective tissue disorders | 6/105 |
| Age, Continuous(years) | 3-DAA + RBV 600 mg |
|---|---|
| Mean | 49.8 ± 13.03 |
| Sex: Female, Male(Participants) | 3-DAA + RBV 600 mg |
|---|---|
| Female | 55 |
| Male | 50 |
No study locations are listed for this record.
Ran from Oct 2015 to primary completion in Oct 2016, 11 months.
Results were first posted in Oct 2017, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 11 months is below that.
Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Ribavirin